Opioid, HIV and Immune System

Immune Defect Clinical Trial

Official title:

Immune Dysfunction in HIV+ Opioid Users

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04304768
• Other study ID #: 20200178
• Status: Recruiting
• Phase: Phase 4
• Start date: November 18, 2020
• Est. completion date: May 31, 2025

Study information

• Verified date: September 2023
• Source: University of Miami
• Contact: Savita Pahwa, MD
• Phone: 3052437732
• Email: spahwa[@]med.miami.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this research is to evaluate blood samples from HIV infected and non-HIV infected people opioid and non opioid users to understand how opioid affect the immune responses (body defenses against infection) to the flu vaccine.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 300
• Est. completion date: May 31, 2025
• Est. primary completion date: May 31, 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

For Opioid (OP) users/non-users:

1. OP users - prescribed opioids for at least the past 90 days; or injecting opioids for at least 90 days

2. Opioid never-users in the past year

Additional criteria for OP users:

1. OP use for 90 days pre-flu vaccination

2. Continued OP use for 4 weeks post flu vaccination For HIV positive participants: 1) HIV infection, as documented by any licensed ELISA kit and confirmed by Western blot at any time prior to study entry. Participants on ART as a result of prior HIV documented infection will not be required to provide proof of diagnosis of HIV infection.

Additional criteria for HIV positive participants:

1. On ART for at least 1 year with plasma pending viral load (VL) <200 copies/mL. Occasional viral blips up to 1000 copies/ml also acceptable provided the patients are on continuing treatment

2. CD4 count available in the prior 6 months and >200/mm3

3. Undetectable viral load (< 200 copies/mL) For HIV negative participants: 1) Documented negative HIV test, either by any licensed ELISA or rapid tests within the past 6 months.

For all participants:

1. Individuals age 18-60 yrs .

2. No history of other immunodeficiency disorders

3. Not on steroid or other immunosuppressive/immunomodulators medications.

4. No active malignancies.

5. No contraindication to receive influenza vaccination (allergy to chicken eggs or to any other substance of the vaccine).

6. Agreeable to receive the influenza vaccination.

7. Agreeable to participate in study for a complete course of study full visits.

8. Able to provide informed consent.

Exclusion Criteria:

1. Contraindication to receive influenza vaccination (allergy to chicken eggs or to any other substance of the vaccine).

2. Non-adherence to ART for HIV+

3. Unable to provide informed consent.

4. Other comorbid conditions such as diabetes mellitus type 2 (DMT2)

5. Influenza vaccination already given during the current vaccination season.

Related Conditions & MeSH terms

• Immune Defect

Intervention

Biological:
• Fluzone Quadrivalent
0.5 ml prefilled syringe administrated intramuscularly

Locations

Country	Name	City	State
United States	University of Miami	Miami	Florida

Sponsors (1)

Lead Sponsor	Collaborator
University of Miami

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the antibody response	Antibody response as measured by the serum vaccine antigen specific hemagglutination inhibition antibody levels.	Baseline, 4 weeks, 6 months
Secondary	Immune activation levels	Activation of T and B cells from peripheral blood mononuclear cells assessed via flow cytometry.	Baseline
Secondary	Inflammation biomarker levels	Plasma levels of Interleukin (IL)-6, IL-8, IL-12, IL-17, IL-22, Tumor necrosis factor (TNF) and monocyte activation markers soluble CD14 and soluble CD163 will be assessed via Magpix. All the biomarkers will be measured in nanograms/milliliter.	Baseline
Secondary	Circulating T follicular helper cell function	T follicular helper cell function measured from peripheral blood mononuclear cells via flow cytometry.	Week 4
Secondary	Circulating T follicular helper cell frequency	T follicular helper cell frequency measured from peripheral blood mononuclear cells via flow cytometry.	Week 4